Jacob S. Van Naarden's Insider Trades & SAST Disclosures
Jacob S. Van Naarden's most recent trade in Lilly(Eli) & Co was a trade of 6,103 Common Stock done at an average price of $869.0 . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jacob S. Van Naarden.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Lilly Oncology | Grant, award, or other acquisition of securities at price $ 869.00 per share. | 10 Feb 2025 | 6,103 | 19,561 (0%) | 0% | 869.0 | 5,303,491 | Common Stock |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Lilly Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 4,108 | 4,108 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Lilly Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,023 | 14,868 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Lilly Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,023 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Lilly Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 811.56 per share. | 01 Feb 2025 | 1,409 | 13,458 (0%) | 0% | 811.6 | 1,143,492 | Common Stock |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Lilly Oncology | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Oct 2024 | 4,302 | 11,845 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Van Naarden S. Jacob | EVP & Pres., Loxo@Lilly | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,023 | 3,023 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | S. Van Naarden Jacob | EVP & Pres., Loxo@Lilly | Grant, award, or other acquisition of securities at price $ 737.26 per share. | 12 Feb 2024 | 2,369 | 16,147 (0%) | 0% | 737.3 | 1,746,569 | Common Stock |
| Lilly(Eli) & Co | Van Naarden S. Jacob | EVP & Pres., Loxo@Lilly | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 3,618 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP & Pres., Loxo@Lilly | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 3,618 | 15,463 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Jacob Van Naarden S. | EVP & Pres., Loxo@Lilly | Payment of exercise price or tax liability using portion of securities received from the company at price $ 645.61 per share. | 01 Feb 2024 | 1,685 | 13,778 (0%) | 0% | 645.6 | 1,087,853 | Common Stock |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP and CEO Loxo@Lilly | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 2,785 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP and CEO Loxo@Lilly | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 2,785 | 13,159 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP and CEO Loxo@Lilly | Payment of exercise price or tax liability using portion of securities received from the company at price $ 335.01 per share. | 16 Feb 2023 | 1,314 | 11,845 (0%) | 0% | 335.0 | 440,203 | Common Stock |
| Lilly(Eli) & Co | Jacob S. Van Naarden | EVP and CEO Loxo@Lilly | Grant, award, or other acquisition of securities at price $ 345.12 per share. | 10 Feb 2023 | 2,407 | 10,374 (0%) | 0% | 345.1 | 830,704 | Common Stock |
| Lilly(Eli) & Co | Jacob S. Van Naarden | SVP, CEO LoxoONC, Pres LlyONC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 5,461 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | SVP, CEO LoxoONC, Pres LlyONC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 5,461 | 10,153 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Jacob S. Van Naarden | SVP, CEO LoxoONC, Pres LlyONC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.84 per share. | 16 Feb 2022 | 2,186 | 7,967 (0%) | 0% | 243.8 | 533,034 | Common Stock |
| Lilly(Eli) & Co | Jacob S. Van Naarden | SVP, CEO LoxoONC, Pres LlyONC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2021 | 3,618 | 3,618 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges